**CARE Checklist of information to include when writing a case report**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Topic**  |  | **Item**  | **Checklist item description**  |  |  | **Reported on Line**  |

**Title 1** The diagnosis or intervention of primary focus followed by the words “case report” . . . . . .3 . . . . . . . . . . . . . . . . . . . .

**Key Words 2** 2 to 5 key words that identify diagnoses or interventions in this case report, including "case report" . . .30

**Abstract 3a** Introduction: What is unique about this case and what does it add to the scientific literature? . . . . . 8-11. . . . . . . . . . .

**(no references) 3b** Main symptoms and/or important clinical findings . . . . . . . . 7-8. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

 **3c** The main diagnoses, therapeutic interventions, and outcomes . . . . . . .5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

 **3d** Conclusion—What is the main “take-away” lesson(s) from this case? . . . . . . . 6-7. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

**Introduction 4** One or two paragraphs summarizing why this case is unique (**may include** reference**s**) . .37 - 47 . . . . . . . . . .

**Patient Information 5a** De-identified patient specific information. .case 1: 52, case 2: 76, case 3: 96, .case 4: 111 . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

 **5b** Primary concerns and symptoms of the patient. . . . . . .case 1:line 58 - 67 , case 2:line 76 - 86, case 3: 96 - 102 , case 4:115 - 124. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

 **5c** Medical, family, and psycho-social history including relevant genetic information . Case 1: line 52, case 2: line 76, case 3: line 96 and 99, case 4: line 112. . . . . . . . . . . . . . . .

 **5d** Relevant past interventions with outcomes . . . . None

**Clinical Findings 6** Describe significant physical examination (PE) and important clinical findings . . Case 1: line 58-61, case 2: line 77-79 , case 3:.line 98, case 4: line 115-117. . . . . . . . . . . . . . . . . . .

**Timeline 7** Historical and current information from this episode of care organized as a timeline . .case 1: line 54, case 2:line 77, case 3: line 97, case 4: line 112 .. . . . . . . . . . . .

**Diagnostic 8a** Diagnostic testing (such as PE, laboratory testing, imaging, surveys). . case 1:58-67, case 2: 80-88, case 3:98-105, case 4: 115-124 .. . . . . . . . . . . . . . . . . . . . . . . . . . .

**Assessment**

 **8b** Diagnostic challenges (such as access to testing, financial, or cultural) . . . .none. . . . . . . . . . . . . . . . . . . . . . . . .

 **8c** Diagnosis (including other diagnoses considered) . . . . . . . case 1 line :67, case 2 :line 85, case 3 :line. 105, case 4 line :126. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

 **8d** Prognosis (such as staging in oncology) where applicable . . . .none. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

**Therapeutic 9a** Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care) .case1 line 69, case 2 line 91, case 3 line 106, case 4 line 128 . . . . . . . . . . . . . . . . . . . **Intervention**

 **9b** Administration of therapeutic intervention (such as dosage, strength, duration) case 1 line.69, case 2 line 90-92, case 3 and case 4 --- . . . . . . . . . . . . . . . . . . . . . . . . . . . .

 **9c** Changes in therapeutic intervention (with rationale) . none . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

**Follow-up and 10a** Clinician and patient-assessed outcomes (if available) . . . . case :1 line 73, case :2 line 93,case :3 line 108, case 4 :line 129. . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . .

**Outcomes**

 **10b** Important follow-up diagnostic and other test results . . Follow-up test results are not mentioned. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

 **No**

**10c** Intervention adherence and tolerability (How was this assessed?) . . . . .not mentioned . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . **10d** Adverse and unanticipated events . . not mentioned. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

**Discussion 11a** A scientific discussion of the strengths AND limitations associated with this case report . line131--138. . . . . . . . . . . . . . . . . . . . . .

 **11b** Discussion of the relevant medical literature **with references**. . .line . 139-141(reference 17). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

 **11c** The scientific rationale for any conclusions (including assessment of possible causes) . line. .156--163 . . . . . . . . . . . . . . . . . . . . .

 **11d** The primary “take-away” lessons of this case report (without references) in a one paragraph conclusion . . .line 174--179 . . . .

**Patient Perspective 12** The patient should share their perspective in one to two paragraphs on the treatment(s) they received . . . .not mentioned . . . .

**Informed Consent 13** Did the patient give informed consent? Please provide if requested . . . yes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  **Yes**